Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 351 - 383 av 383 resultater
Tid
Selskap
Tittel
Sektor
Kategori
10 Aug 2021
07:00 CEST
VALNEVA SE
Valneva publie ses résultats financiers du premier semestre 2021 et fait un point sur ses activités
20103010 Biotechnology
New
10 Aug 2021
07:00 CEST
VALNEVA SE
Valneva Reports H1 2021 Financial Results and Provides Business Update
20103010 Biotechnology
New
05 Aug 2021
07:00 CEST
VALNEVA SE
Valneva annonce des résultats positifs pour l’étude pivot de Phase 3 de son candidat vaccin à injection unique contre le chikungunya
20103010 Biotechnology
Products and services
05 Aug 2021
07:00 CEST
VALNEVA SE
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
20103010 Biotechnology
Products and services
03 Aug 2021
18:35 CEST
VALNEVA SE
Déclaration d’actions et de droits de vote de la société Valneva SE – Juillet 2021
20103010 Biotechnology
Legal
29 Jul 2021
07:00 CEST
VALNEVA SE
Valneva Appoints Peter Buhler as Chief Financial Officer
20103010 Biotechnology
Journal / appointments
29 Jul 2021
07:00 CEST
VALNEVA SE
Valneva nomme Peter Buhler au poste de Directeur Financier
20103010 Biotechnology
Journal / appointments
19 Jul 2021
07:00 CEST
VALNEVA SE
Valneva et Pfizer finalisent le recrutement de l’essai de Phase 2 pour leur candidat vaccin contre la maladie de Lyme
20103010 Biotechnology
Products and services
19 Jul 2021
07:00 CEST
VALNEVA SE
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
20103010 Biotechnology
Products and services
07 Jul 2021
19:00 CEST
VALNEVA SE
VALNEVA: Déclaration d’actions et de droits de vote – Juin 2021
20103010 Biotechnology
Legal
07 Jul 2021
17:45 CEST
VALNEVA SE
Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
20103010 Biotechnology
Products and services
07 Jul 2021
17:45 CEST
VALNEVA SE
Valneva reçoit le statut « Breakthrough Therapy » de la FDA pour son candidat vaccin à injection unique contre le chikungunya
20103010 Biotechnology
Products and services
06 Jul 2021
17:45 CEST
VALNEVA SE
Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations
20103010 Biotechnology
Other subject
06 Jul 2021
17:45 CEST
VALNEVA SE
Valneva renforce ses équipes dirigeantes et nomme Vincent Dequenne Vice-Président Senior en charge des Opérations Industrielles et Joshua Drumm Vice-Président des Relations Investisseurs
20103010 Biotechnology
Other subject
05 Jul 2021
17:45 CEST
VALNEVA SE
Valneva organise un symposium scientifique sur ses candidats vaccins contre la COVID-19 et le chikungunya lors du 31ème Congrès européen de microbiologie clinique et des maladies infectieuses
20103010 Biotechnology
Alliances and agreements
05 Jul 2021
17:45 CEST
VALNEVA SE
Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases
20103010 Biotechnology
Alliances and agreements
01 Jul 2021
07:00 CEST
VALNEVA SE
Valneva poursuit ses discussions avec la Commission Européenne pour son candidat vaccin inactivé contre la COVID-19
20103010 Biotechnology
Other subject
01 Jul 2021
07:00 CEST
VALNEVA SE
Valneva Continues Ongoing Discussions with the European Commission for Inactivated COVID-19 Vaccine Candidate
20103010 Biotechnology
Other subject
23 Jun 2021
17:40 CEST
VALNEVA SE
Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale
20103010 Biotechnology
General meeting / Board Meeting
23 Jun 2021
17:40 CEST
VALNEVA SE
Valneva Announces Successful Outcome of its AGM
20103010 Biotechnology
General meeting / Board Meeting
11 Jun 2021
18:10 CEST
VALNEVA SE
Valneva annonce la résiliation de son contrat de liquidité avec Oddo BHF et Natixis et présente son bilan de fin de contrat
20103010 Biotechnology
Other subject
11 Jun 2021
18:10 CEST
VALNEVA SE
Valneva Announces Termination of Liquidity Contract with Oddo BHF and Natixis and Publishes End of Contract Statement
20103010 Biotechnology
Other subject
10 Jun 2021
07:00 CEST
VALNEVA SE
Valneva Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate
20103010 Biotechnology
Products and services
10 Jun 2021
07:00 CEST
VALNEVA SE
Valneva finalise le recrutement l’étude de Phase 3 sur l’homogénéité des lots cliniques de son candidat vaccin contre le chikungunya
20103010 Biotechnology
Products and services
07 Jun 2021
18:00 CEST
VALNEVA SE
Déclaration d’actions et de droits de vote de la société Valneva SE – Mai 2021
20103010 Biotechnology
Legal
03 Jun 2021
19:15 CEST
VALNEVA SE
Valneva finalise le recrutement de Phase 3 pour son candidat vaccin inactivé contre la COVID-19
20103010 Biotechnology
Products and services
03 Jun 2021
19:15 CEST
VALNEVA SE
Valneva Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candidate
20103010 Biotechnology
Products and services
02 Jun 2021
08:30 CEST
VALNEVA SE
Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale et la tenue de cette réunion à huis clos
20103010 Biotechnology
General meeting / Board Meeting
02 Jun 2021
08:30 CEST
VALNEVA SE
Valneva Announces the Availability of Documentation for its Combined General Meeting to be held as a closed meeting
20103010 Biotechnology
General meeting / Board Meeting
20 May 2021
07:00 CEST
VALNEVA SE
Valneva Reports Q1 2021 Financial Results and Business Update
20103010 Biotechnology
Other subject
20 May 2021
07:00 CEST
VALNEVA SE
Valneva publie ses résultats financiers du premier trimestre 2021 et fait un point sur ses activités
20103010 Biotechnology
Other subject
19 May 2021
18:05 CEST
VALNEVA SE
Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK
20103010 Biotechnology
Products and services
19 May 2021
18:05 CEST
VALNEVA SE
Valneva va participer à la première étude mondiale pour une vaccination de rappel contre la COVID-19 au Royaume-Uni
20103010 Biotechnology
Products and services
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
6
7
8
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva